For the latest updates on our ongoing response to COVID-19, please click here.

HCV STAT Program

HCV STAT Program: Simplification and Test and Treat Strategies Towards Hepatitis C Elimination

Thank you for your interest in the HCV STAT program. The application window has closed as of Sunday June 30 at 11:59PM US Pacific. We will review all Letters of Intent received before this deadline and will inform applicants of the outcome in the coming weeks.

The development of highly-effective direct-acting antivirals (DAAs) have revolutionized the care of patients with hepatitis C virus (HCV) over the last few years, providing cure rates greater than 95% with few side effects and rare treatment discontinuations. This advancement in HCV care, combined with increased access to treatment, have led many countries to implement strategies toward HCV elimination in alignment with the World Health Organization (WHO) goal of eliminating viral hepatitis as a public health threat globally by 20301.

HCV screening, linkage to care, and treatment access still remain a challenge due to health system, provider, societal, and patient barriers. According to the WHO, key success factors for large-scale HCV treatment and care delivery include the use of simplified and standardized HCV treatment algorithms and decentralized care in primary care settings in the community, in addition to collaboration and commitment of all involved stakeholders2.

Gilead supports the efforts of governments and partners with professional organizations, patient advocacy groups, payers and healthcare professionals who have declared their intention and commitment to work toward the goal of eliminating viral hepatitis.

The LEGA-C platform, “Local Elimination Programs Leading to Global Action in HCV”, including the ongoing programs CITE, SCALE, CHIME, and NoCo, demonstrates Gilead’s commitment to support local actions in HCV elimination. More than 100 investigator-sponsored research (ISR) studies have been funded by Gilead, focused on screening, linkage to care and micro-elimination.

To further strengthen this support and commitment, the Gilead Medical Affairs team is launching a fifth program, Simplification and Test and Treat Strategies Towards Hepatitis C Elimination (STAT), which will support projects that focus on ways to overcome barriers in hepatitis C care. The new once-daily, pan-genotypic treatment regimens enable treatment simplification and decentralization that could lead to expansion in hepatitis C care and additional progress towards the elimination goal1,3.

The STAT program aims to fund approximately 15 projects worldwide, with a total budget of US $10,000,000. Successful projects should demonstrate clear objectives, defined timelines, a scientifically appropriate care pathway plan (i.e., protocol), and proposed data generation which has relevance to the medical community and policy makers.

Key Dates & Program Specifics

  • 11 April 2019: LOI submission window opens
  • 30 June 2019: LOI submission window closes
  • LOI should be submitted to using the template provided below

Gilead plans to approve awards for these research proposals, dependent upon availability of funds and receipt of meritorious applications. Awards shall be for research purposes only.

Questions about the announcement or application process should be submitted to your local Gilead Medical Scientist or

1. WHO. Global Hepatitis Report 2017 Available at: (accessed April 2018)

2. WHO. Global Health Sector Strategy on Viral Hepatitis 2016-2021 towards ending viral hepatitis Available at: (accessed January 2019)

3. Kapadia SN and Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther. 2018 Aug; 40(8):1234-45